Nia Impact Advisors, LLC Crispr Therapeutics Ag Transaction History

Nia Impact Advisors, LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 03, 2023	SELL	$41.0 - $56.12 $106,518 - $145,799	-2,598 Reduced 31.61%	5,620 $254,000
Q4 2022 Feb 09, 2023	SELL	$39.19 - $65.67 $182,625 - $306,022	-4,660 Reduced 36.19%	8,218 $334,000
Q3 2022 Nov 14, 2022	SELL	$61.1 - $83.78 $1.96 Million - $2.69 Million	-32,158 Reduced 71.41%	12,878 $842,000
Q2 2022 Aug 05, 2022	SELL	$43.23 - $73.83 $1.52 Million - $2.59 Million	-35,046 Reduced 43.76%	45,036 $2.74 Million
Q1 2022 May 11, 2022	BUY	$53.19 - $79.24 $929,388 - $1.38 Million	17,473 Added 27.91%	80,082 $5.03 Million
Q4 2021 Feb 11, 2022	BUY	$70.09 - $111.29 $147,889 - $234,821	2,110 Added 3.49%	62,609 $3.88 Million
Q3 2021 Nov 16, 2021	BUY	$110.2 - $156.64 $2.27 Million - $3.23 Million	20,608 Added 51.66%	60,499 $6.77 Million
Q2 2021 Aug 16, 2021	BUY	$100.84 - $161.89 $201,579 - $323,618	1,999 Added 5.28%	39,891 $6.46 Million
Q1 2021 Jun 16, 2021	BUY	$110.72 - $210.04 $488,496 - $926,696	4,412 Added 13.18%	37,892 $4.62 Million
Q4 2020 Jan 25, 2021	BUY	$79.67 - $173.23 $2.67 Million - $5.8 Million	33,480 New	33,480 $6.51 Million

491

58M

1.1M

1.9M

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $3.61B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

Get notified when there are updates to the investment portfolio of Nia Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Nia Impact Advisors, LLC with notifications on news.